8-K: Neuraxis Settles Long-Standing Lawsuits for $750,000, Issues Shares from Warrant Exercises and Preferred Stock Conversions

Neuraxis, Inc. settles multiple lawsuits for $750,000 payable in monthly installments, and issues common stock from warrant exercises and preferred stock conversions.

Summary

• Neuraxis, Inc. has entered into a settlement agreement to resolve lawsuits initiated between February 2019 and July 2022.
• The settlement amount totals $750,000, payable in 12 equal monthly installments of $62,500 starting in January 2026.
• The Releasing Parties have agreed to waive all claims against Neuraxis and other Released Parties.
• Neuraxis received approximately $1 million from warrant exercises between May 20 and May 21, 2025, and issued 430,580 shares of common stock.
• Additionally, holders of Series B Preferred Stock converted their shares into 342,016 shares of common stock.

Sentiment

Score: 6

Explanation: The settlement removes a legal overhang, which is positive. However, the financial obligation and dilution are negatives. The warrant exercises are a positive sign of investor confidence.

Positives

• The settlement resolves long-standing legal disputes, removing uncertainty and potential future legal costs.
• The $1 million received from warrant exercises strengthens the company's financial position.
• The issuance of common stock from warrant exercises and preferred stock conversions could increase liquidity.

Negatives

• The $750,000 settlement represents a significant financial obligation for the company, payable over 12 months.
• The issuance of new shares dilutes existing shareholders' ownership.

Risks

• Failure to make timely settlement payments could result in the full remaining amount becoming immediately due and payable, potentially leading to legal action.
• The dilution of existing shareholders' equity from the issuance of new shares could negatively impact the stock price.

Future Outlook

The company has resolved outstanding legal issues and strengthened its balance sheet through warrant exercises. The company will need to manage the settlement payments over the next year.

Management Comments

• No specific management comments were included in the document.

Industry Context

Settling legal disputes can be a common occurrence for companies, especially in the healthcare sector where litigation is frequent. Raising capital through warrant exercises is a typical method for companies to fund operations and growth.

Comparison to Industry Standards

• Settlement amounts vary widely depending on the nature and severity of the claims. Without knowing the specifics of the lawsuits, it's difficult to assess whether the $750,000 settlement is favorable or unfavorable compared to industry benchmarks.
• Warrant exercises are a common financing tool, but the impact on the stock price depends on the exercise price and the market's perception of the company's prospects.
• Comparing Neuraxis's situation to similar small-cap healthcare companies that have recently settled lawsuits and raised capital would provide a more accurate benchmark.

Legal Proceedings

• The document details the settlement of lawsuits initiated by Ritu Bhambhani, M.D., and associated entities against Neuraxis, Inc., Acclivity Medical LLC, Ryan Kuhlman, Dragonslayer Strategies LLC, and Joy Long.

Stakeholder Impact

• Shareholders will experience dilution from the issuance of new shares.
• The settlement resolves uncertainty for all parties involved in the litigation.
• The company's creditors may be impacted by the new financial obligation.

Next Steps

• Neuraxis will make monthly settlement payments of $62,500 starting in January 2026.
• Bhambhani LLC, Box Hill Surgery Center LLC, Pain and Spine Specialists of Maryland, LLC, SimCare ASC, LLC, NeurAxis, Acclivity, and Long will file a Stipulation of Dismissal in the Medical Practice Entities litigation within fourteen (14) calendar days after the agreement is fully executed.

Key Dates

Keywords

settlement agreement, warrant exercises, preferred stock conversion, common stock, lawsuits, Neuraxis